Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Debate 47A - Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
Yes
from Section V - Cervical Cancer
Published online by Cambridge University Press: 20 July 2023
Book contents
- 50 Big Debates in Gynecologic Oncology
- 50 Big Debates in Gynecologic Oncology
- Copyright page
- Contents
- Contributors
- Section I Perioperative Management
- Section II Screening, Prevention, and Early Diagnosis
- Section III Ovarian Cancer
- Section IV Endometrial Cancer
- Section V Cervical Cancer
- Debate 42A Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 42B Is there a Role for Minimally Invasive Radical Hysterectomy for Management of Cervical Cancer?
- Debate 43A Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 43B Is Radical Surgery or Parametrectomy Needed for Early-stage FIGO IA2 and Microscopic IB1 Cervical Cancer?
- Debate 44A What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 44B What is the Best Management Option for Young Women with Stage IB2 Cervical Cancer Who Wish to Preserve Fertility?
- Debate 45A Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 45B Should Adjuvant Hysterectomy be Performed for Patients with Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiotherapy?
- Debate 46A What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 46B What is the Best Initial Treatment for Stage IB3 to IIB Cervical Cancer?
- Debate 47A Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Debate 47B Is there a Role for Immunotherapy in Treatment of Cervical Cancer?
- Section VI Vaginal and Vulvar Cancer
- Index
- References
Summary
Cervical carcinomas (CC) arise in large part due to infection with human papillomaviruses (HPV), with persistence of viral oncogenic proteins E6 and E7 in most if not all CC. These proteins serve as a source of “foreign” antigens, generating a strong rationale for immunotherapeutic approaches. A number of approaches including cancer vaccines, adoptive cell therapy, and immune checkpoint blockade have been explored in cervical cancer and in pre-cancerous lesions, each demonstrating an ability to induce deep and durable responses, though benefits have been limited to a minority of patients to date. Herein we summarize the results of these studies, discuss ongoing combination trials, and provide perspectives for future of immunotherapy in cervical cancer.
- Type
- Chapter
- Information
- 50 Big Debates in Gynecologic Oncology , pp. 285 - 287Publisher: Cambridge University PressPrint publication year: 2023
References
Chung, HC, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J Clin Oncol 2019;37:1470–1478.CrossRefGoogle ScholarPubMed
Naumann, RW, et al. Safety and efficacy of nivolumab monotherapy in recurrent or metastatic cervical, vaginal, or vulvar carcinoma: results from the phase I/II Check Mate 358 Trial. J Clin Oncol 2019;37:2825–2834.CrossRefGoogle ScholarPubMed
Trimble, CL, et al. Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial. Lancet 2015;386:2078–2088.CrossRefGoogle ScholarPubMed
Stevanovic, S, et al. Complete regression of metastatic cervical cancer after treatment with human papillomavirus-targeted tumor-infiltrating T cells. J Clin Oncol 2015;33:1543–1550.CrossRefGoogle ScholarPubMed
Doran, SL, et al. T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase I/II study. J Clin Oncol 2019;37:2759–2768.CrossRefGoogle ScholarPubMed